Atlas Trials

Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma

Clinical trial NCT07581509 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07581509
Sponsor
Biocon Biologics UK PLC
Status
NOT_YET_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Patients With Stage IIB, IIC, and Stage III Melanoma Following Complete Resection (Adjuvant Settings)
Start date
2026-08-01
Primary completion
2027-12-15
Enrollment
138

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.